There is some evidence suggesting a worse outcome with tamoxifen for women with ER-positive tumours that lack progesterone receptor (PgR), and/or exhibit overexpression of growth factor receptors such as human epidermal growth factor receptors 1and 2 (EGFR and HER-2/neu) (11,12). The gene discussed is ESR1; the disease is neoplasm.